Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer

Fig. 1

Identification of EC-associated CTA genes. A Differential genes between tumor and para-cancer; Red dots indicate genes significantly overexpressed in the tumor, and blue dots indicate genes significantly downregulated in para-cancer. The screening threshold is (log2|fold-change| > 1 and p-adjust < 0.05). The horizontal gray dashed line means p-adjust = 0.05, and the vertical gray dashed line means log2|fold-change | = 1. B ssGSEA enrichment analysis based on CTA genes that upregulated in EC showed a strong correlation between CTA enrichment scores and clinical features. C Results of survival analysis based on CTA enrichment scores. A two-sided log-rank test is used to compare patient survival between the two groups. D Differential genes between the CTAhigh group and CTAlow group; red dots indicate genes significantly overexpressed in the CTAhigh group, and blue dots indicate genes significantly overexpressed in the CTAlow group; the screening threshold is (log2|fold-change| > 1 and p-adjust < 0.05). The horizontal gray dashed line means p-adjust = 0.05, and the vertical gray dashed line means log2|fold-change| = 1. E Heat map shows the CTA genes that are co-upregulated in the CTAhigh group and EC (F) Univariate cox regression analysis of the CTA gene in E plot. G Differential gene expression of three genes (TTK, LY6K, NOL4) in stage 1 EC tissues (GEO database) and benign samples (GSE17025). ***P < 0.001, by Wilcoxon tests. H Survival analysis of TTK based on EC gene expression profile from TCGA database. A two-sided log-rank test is used to compare patient survival between the two groups. I TTK expression has potential diagnostic significance in distinguishing early-stage EC tissues from benign tissues. The ROC curve was created using gene expression data from GSE17025

Back to article page